An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM) (ixCELL DCM)
This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
First received: August 20, 2012
Last updated: March 6, 2017
Last verified: March 2017
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is ongoing, but not recruiting participants.|
|Estimated Study Completion Date:||November 2018|
|Primary Completion Date:||February 2016 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Received:||November 3, 2016|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Patel AN, Henry TD, Quyyumi AA, Schaer GL, Anderson RD, Toma C, East C, Remmers AE, Goodrich J, Desai AS, Recker D, DeMaria A; ixCELL-DCM Investigators. Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial. Lancet. 2016 Jun 11;387(10036):2412-21. doi: 10.1016/S0140-6736(16)30137-4. Epub 2016 Apr 5. Erratum in: Lancet. 2016 Jun 11;387(10036):2382.